新型冠状病毒肺炎抗病毒药物的治疗药物监测及药代动力学研究进展

doi:10.12092/j.issn.1009-2501.2020.05.014

摘要/Abstract

摘要： 近期新型冠状病毒(SARS-CoV-2)感染所致肺炎疫情的爆发给各国公共卫生和治理带来了重大挑战。目前临床上尚无针对SARS-CoV-2的特效药,采用的多为既往治疗严重急性呼吸综合征(SARS)和中东呼吸综合症(MERS)的抗病毒药物。本文旨在对有关抗病毒药物及其药代动力学特征进行整理和分析,并对其开展治疗药物监测(TDM)的特点和必要性进行探讨,从而为抗SARS-CoV-2治疗中的用药安全提供参考。

关键词: 关键词新型冠状病毒肺炎, 抗病毒药物, 治疗药物监测, 不良反应, 药代动力学

Abstract: The recent outbreak of pneumonia caused by new coronavirus (SARS-CoV-2) infection has brought major challenges to public health and governance in various countries. At present, there is no clinically specific drug for SARS-CoV-2, and most of the antiviral drugs used are drugs for the treatment of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS). This article aims to organize and analyze the antiviral drugs and their pharmacokinetic characteristics, and to discuss the characteristics and necessity of therapeutic drug monitoring (TDM), so as to provide a reference for the safety of anti-SARS-CoV-2 treatment.

Key words: new coronavirus pneumonia, antiviral drugs, therapeutic drug monitoring, adverse reactions, pharmacokinetics

中图分类号:

张露, 林良沫, 刘可可, 黄娅敏, 黄行行, 杨永榆, 肖坚. 新型冠状病毒肺炎抗病毒药物的治疗药物监测及药代动力学研究进展[J]. 中国临床药理学与治疗学, 2020, 25(5): 566-575.

ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian. Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.

参考文献

[1]Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 [J]. Nat Microbiol, 2020, 5(4): 536-544.
[2]国家卫生健康委员会.新型冠状病毒肺炎诊疗方案 (试行第七版) [S]. 2020.
[3]Tchesnokov EP, Feng JY, Porter DP, et al. Mechanism of Inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir [J]. Viruses, 2019, 11(4): 326.
[4]Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase [J]. Proc Jpn Acad Ser B Phys Biol Sci, 2017, 93(7): 449-463.
[5]Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States [J]. N Engl J Med, 2020, 382(10): 929-936.
[6]Sheahan TP, Sims AC, Leist SR, et al.Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV [J]. Nat Commun, 2020, 11(1): 222.
[7]刘奇, 夏帅, 姜世勃. 抗新型冠状病毒2019-nCoV新药的研发 [J]. 中国临床药理学与治疗学, 2020, 25(3): 241-245.
[8]Xu Z, Peng C, Shi Y, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCoV main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation [Z]. Biorxiv, 2020. https://doi.org/10.1101/2020.01.27.921627.
[9]广东省药学会. 新型冠状病毒肺炎患者血药浓度检测技术指引 [J/OL]. 今日药学:1-7[2020-04-19]. http://kns.cnki.net/kcms/detail/44.1650.R.20200214.1554.002.html.
[10]田成, 向明. 瑞德西韦与干扰素α联用治疗新型冠状病毒肺炎的可行性分析 [J/OL]. 医药导报:1-13[2020-04-22]. http://kns.cnki.net/kcms/detail/42.1293.R.20200303.1518.004.html.
[11]靳秀红, 汤昱, 梁利红, 等. 重组人干扰素α1b不同给药方式治疗儿童病毒性肺炎的临床观察 [J]. 中国药房, 2014, 25(28): 2607-2610.
[12]刘鉴峰, 刘金剑, 褚丽萍, 等. 雾化吸入干扰素α1b在兔体内的分布及代谢途径 [J]. 医药导报, 2013, 32(1): 1-5.
[13]Maasilta P, Halme M, Mattson K, et al. Pharmacokinetics of inhaled recombinant and natural alpha interferon [J]. Lancet, 1991, 337(8737): 371.
[14]Norris V, Warrington S, Boyce M.Effect of inhaled interferon Beta-1a on carbon monoxide transfer factor in healthy volunteers [J]. J Interferon Cytokine Res, 2016, 36(2): 113-119.
[15]Abdel-Moneim A, Abood A, Abdel-Gabaar M, et al. Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients [J]. Clin Exp Hepatol, 2018, 4(3): 191-196.
[16]Wei L, Shang J, Ma Y, et al. Efficacy and safety of 12-week interferon-based danoprevir regimen in patients with Genotype 1 chronic hepatitis C [J]. J Clin Transl Hepatol, 2019, 7(3): 221-225.
[17]Snell NJ. Adverse reactions to inhaled drugs [J]. Respir Med, 1990, 84(5): 345-348.
[18]陈泳伍, 唐丽琴, 张圣雨, 等. α干扰素雾化治疗在新型冠状病毒肺炎中的合理使用及药学监护 [J/OL]. 中国医院药学杂志:1-5[2020-04-19]. http://kns.cnki.net/kcms/detail/42.1204.R.20200224.1905.007.html.
[19]陈勇川. 新型冠状病毒肺炎治疗药物研发现状 [J]. 中国药业, 2020, 29(6): 1-7.
[20]Krishna S, White NJ.Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications [J]. Clin Pharmacokinet, 1996, 30(4): 263-299.
[21]Sortica VA, Lindenau JD, Cunha MG, et al. The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment [J]. Pharmacogenomics, 2016, 17(17): 1903-1911.
[22]Verbeeck RK, Junginger HE, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride [J]. J Pharm Sci, 2005, 94(7): 1389-1395.
[23]Wang M, Cao R, Zhang L, et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J]. Cell Res, 2020, 30(3): 269-271.
[24]Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials [J]. Am J Med, 1983, 75(1A): 40-45.
[25]Borges MC, Castro LA, Fonseca BA. Chloroquine use improves dengue-related symptoms [J]. Mem Inst Oswaldo Cruz, 2013, 108(5): 596-599.
[26]AlKadi HO. Antimalarial drug toxicity: a review [J]. Chemotherapy, 2007, 53(6): 385-391.
[27]徐晓涵, 翟所迪, 杨丽. 新型冠状病毒肺炎治疗中抗病毒药物的合理使用 [J]. 中国医院用药评价与分析, 2020, 20(2): 129-133.
[28]Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update [J]. Antiviral Res, 2014,107: 84-94.
[29]李洋, 赵立. 阿比多尔抗呼吸道病毒的药理作用与体外和体内疗效研究现状 [J]. 中国临床药理学杂志, 2019, 35(17): 1964-1968.
[30]李丹, 宋伟, 吴杰, 等. 新型冠状病毒肺炎(COVID-19)患者抗病毒用药监护的研究进展 [J/OL]. 现代药物与临床:1-6[2020-04-19]. http://kns.cnki.net/kcms/detail/12.1407.R.20200409.1143.003.html.
[31]刘宏博, 曲文秀, 李胜岐, 等. 盐酸阿比朵尔片治疗流行性感冒的多中心随机双盲平行对照临床研究 [J]. 中国临床药理学杂志, 2006, 22(6): 403-405.
[32]郭玉娇, 胡静, 周颖, 等. 洛匹那韦/利托那韦在治疗新型冠状病毒肺炎中的应用价值 [J]. 临床药物治疗杂志, 2020, 18(3): 72-76.
[33]Pasquau LJ, Hidalgo TC. Chemical characteristics, mechanism of action and antiviral activity of darunavir [J]. Enferm Infecc Microbiol Clin, 2008, 10: 3-9.
[34]张笑影. 洛匹那韦在中国成人HIV-1感染者体内的药动学和药效学研究 [D]. 北京协和医学院, 2014.
[35]Daniel GDR, Blanco F, Garcia-Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir [J]. Aids Patient Care Stds, 2003, 17(9): 443-445.
[36]Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens [J]. J Acquir Immune Defic Syndr, 2003, 33(5): 594-600.
[37]Gutiérrez F, Padilla S, Navarro A, et al. Lipid abnormalities in HIV-Infected patients and lopinavir plasma concentrations [J]. J Acquir Immune Defic Syndr, 2004, 36(5): 1107-1109.
[38]Torti C, Quiros-Roldan E, Tirelli V, et al. Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients [J]. AIDS Patient Care STDS, 2004, 18(11): 629-634.
[39]柴淑贞. 利托那韦在国人体内的药代动力学研究 [D]. 郑州大学, 2005.
[40]黄晓婕, 杨小东, 周怡宏, 等. 洛匹那韦/利托那韦在艾滋病成人经治病人中的临床应用进展 [J]. 中国艾滋病性病, 2017, 23(9): 869-872.
[41]徐永祥, 沈利汉, 韩伟超, 等. 洛匹那韦利托那韦治疗危重型新型冠状病毒肺炎的药学监护 [J/OL]. 中国临床药理学杂志:1-4[2020-04-19]. https://doi.org/10.13699/j.cnki.1001-6821.2020.07.054.
[42]刘颖, 苏娜, 沈超, 等. 洛匹那韦/利托那韦用于病毒感染性疾病的有效性和安全性文献分析 [J/OL]. 医药导报:1-15[2020-04-22]. http://kns.cnki.net/kcms/detail/42.1293.R.20200228.1420.006.html.
[43]Pulido F, Estrada V, Baril JG, et al.Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks [J]. HIV Clin Trials, 2009, 10(2): 76-87.
[44]Kakuda TN, Brochot A, Tomaka FL, et al.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir [J]. J Antimicrob Chemother, 2014, 69(10): 2591-2605.
[45]Boffito M, Jackson A, Amara A, et al.Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation [J].Antimicrob Agents Chemother, 2011, 55(9): 4218-4223.
[46]Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers [J]. J Clin Pharmacol, 2007, 47(4): 479-484.
[47]Molto J, Curran A, Miranda C, et al.Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients [J]. J Antimicrob Chemother, 2018, 73(3): 732-737.
[48]Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study [J]. Lancet HIV, 2018, 5(6): e291-e300.
[49]Khadem TM, van Manen RP, Brown J. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database [J]. Pharmacotherapy, 2014, 34(12): 1324-1329.
[50]Baede-van DP, Hugen PW, Verweij-van WC, et al. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients [J]. AIDS, 2001, 15(8): 991-998.
[51]Kamboj S, Sethi S, Rana V. A spray dried Nelfinavir Mesylate particles for enhanced oral bioavailability: Systematic formulation optimization and in-vivo performance [J]. Colloids Surf B Biointerfaces, 2019, 176: 288-299.
[52]Hirt D, Mentre F, Tran A, et al.Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients [J]. Br J Clin Pharmacol, 2008, 65(4): 548-557.
[53]Weidle PJ, Zeh C, Martin A, et al. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir [J]. Antimicrob Agents Chemother, 2011, 55(11): 5168-5171.
[54]Aarnoutse RE, Droste JA, van Oosterhout JJ, et al.Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers [J]. Br J Clin Pharmacol, 2003, 55(2): 115-125.
[55]Mira JA, Macias J, Giron-Gonzalez JA, et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C [J]. J Antimicrob Chemother, 2006, 58(1): 140-146.
[56]冯穗芬, 魏毅, 刘建辉. 冠状病毒RNA聚合酶抑制剂--利巴韦林的构效关系分析 [J]. 临床药物治疗杂志, 2020, 18(2): 46-49.
[57]王先堃, 孙娜, 陈志海. 法匹拉韦抗病毒治疗研究进展 [J]. 中国新药杂志, 2019, 28(15): 1824-1827
.[58]Polepally AR, Badri PS, Eckert D, et al. Effects of mild and moderate renal impairment on ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin pharmacokinetics in patients with chronic HCV infection [J]. Eur J Drug Metab Pharmacokinet, 2017, 42(2): 333-339.
[59]Aouri M, Moradpour D, Cavassini M, et al.Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir [J]. Antimicrob Agents Chemother, 2013, 57(7): 3147-3158.
[60]熊堉, 蒋敏, 边原, 等. 探索利巴韦林治疗新型冠状病毒肺炎的有效性和安全性:基于既往冠状病毒治疗的总结 [J/OL]. 医药导报:1-13[2020-04-19]. http://kns.cnki.net/kcms/detail/42.1293.R.20200213.0901.002.html.
[61]Gupta SK, Kantesaria B, Glue P. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment [J]. Drug Discov Ther, 2013, 7(4): 158-163.
[62]靳凡, 谢静, 陈锐, 等. 瑞德西韦治疗冠状病毒感染的研究进展 [J/OL]. 协和医学杂志:1-9[2020-04-28]. http://kns.cnki.net/kcms/detail/11.5882.R.20200227.1257.002.html.
[63]Mulangu S, Dodd LE, Davey RJ, et al. A randomized, controlled trial of ebola virus disease therapeutics [J]. N Engl J Med, 2019, 381(24): 2293-2303.
[64]Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses [J]. Antivir Res, 2018,153: 85-94.
[65]赵旭, 周辛波, 钟武, 等. 抗病毒药物--法匹拉韦 [J]. 临床药物治疗杂志, 2015, 13(4): 16-20.
[66]Nagata T, Lefor AK, Hasegawa M, et al. Favipiravir: a new medication for the Ebola virus disease pandemic [J]. Disaster Med Public Health Prep, 2015, 9(1): 79-81.